Treatment-related grade 3 or higher TEAEs in Arm 3 (vedolizumab plus nivolumab plus ipilimumab) were diarrhea in 2 patients; and colitis, fatigue, increased ALT, increased international normalized ratio, decreased platelet count, hyperuricemia, hyponatremia, hypophysitis, autoimmune hepatitis, immune-mediated hepatitis, anemia, eosinophilia, and leukocytosis in 1 patient each. This evidence concerns the gene GPT and colitis.